Clinical trials: GFAP
Fatigue in Multiple Sclerosis, Multiple Sclerosis
Fatigue in Multiple Sclerosis and Its Relationship to Inflammatory and Neurodegenerative Markers of the Disease
The study is focused on several independent quantifiable biomarkers (sNfL, sGFAP, mitochondrial activity, genetics and fatigue tests) to obtain more detailed information about MS and its progression.
- Conditions
- Fatigue in Multiple Sclerosis, Multiple Sclerosis, Neurofilaments Light Chains, GFAP
- Trial name
- MITOFATIGUE (NCT07025122)
- Where
- Slovakia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Martin
Mild Traumatic Brain Injury (mTBI)
Implementation of Biomarker-Based Care for mTBI - IMPACTS-BRAINI Study
This study aims to evaluate the real-world applicability and clinical added value of a new management pathway for patients presenting to the emergency department (ER) with mild traumatic brain injury (mTBI).
- Trial name
- IMPACTS-BRAINI (NCT07311486)
- Testing
- GFAP and UCH-L1
- Where
- Spain
- Volunteers
- 1,000 people
- Sponsor
- Hospital Universitario 12 de Octubre
Brain Injuries, Traumatic, Brain Injuries, Acute
Critical Hyperacute Assessment Research On Neurobiomarker Kinetics in Acute Brain Injury
Traumatic brain injury (TBI) and other conditions that reduce blood flow to the brain - such as cardiac arrest (CA) - are life-threatening medical emergencies.
- Conditions
- Brain Injuries, Traumatic, Brain Injuries, Acute, Hypoxia, Brain, Cardiac Arrest (CA)
- Trial name
- CHARON (NCT07782216)
- Where
- 4 sites in Hungary
- Volunteers
- 477 people
- Sponsor
- University of Pecs
Multiple Sclerosis, NMO Spectrum Disorder
China National Registry of Neuro-Inflammatory Diseases
Central nervous system (CNS) idiopathic inflammatory demyelinating diseases (IDD) are mainly diseases caused by autoimmune factors that result in CNS demyelination damage and loss.
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Clinically Isolated Syndrome, CNS Demyelinating Autoimmune Diseases
- Trial name
- CNRID (NCT05154370)
- Testing
- Intravenous steroid
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Beijing Tiantan Hospital
Cardiac Surgery Requiring Cardiopulmonary Bypass, Brain Injury
The Association Between Tau & GFAP and Postoperative Neurological Impairment in Patients Undergoing Cardiac Surgery
Patients born with heart defects often undergo surgical procedures on a heart lung machine. With improvements in medical and surgical management, their survival has significantly improved, but their brain insult has not been paid…
- Conditions
- Cardiac Surgery Requiring Cardiopulmonary Bypass, Brain Injury, Congenital Heart Defect
- Trial name
- NCT06899971
- Testing
- Collecting discarded blood samples
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Boston Children's Hospital
NMDAR Autoimmune Encephalitis, LGI1 Antibody Associated Encephalitis
Medium-term Effects of Treatments in Autoimmune Encephalitis
Autoimmune encephalitides are severe neurological disorders requiring urgent treatment, even though there is no standard guideline by lack of empirical evidence.
- Conditions
- NMDAR Autoimmune Encephalitis, LGI1 Antibody Associated Encephalitis, CASPR2-Antibody, IgLON5
- Trial name
- META (NCT07133113)
- Testing
- We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
Dexmedetomidine
Dexmedetomidine and Neuroprotection in Children Undergoing General Anesthesia
Neuroapoptosis is induced by the administration of anesthetic agents to the young brain. Recent studies showed that the a2-adrenoceptor agonist, dexmedetomidine plays a trophic role during development and is neuroprotective in…
- Trial name
- NCT03234660
- Testing
- Dexmedetomidine Hydrochloride, control
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Sleep Apnea, Obstructive
Biological and Cognitive Marker of Neurodegeneration in Obstructive Sleep Apnea Patients
The goal of this observational study is to investigate biomarkers and neurocognitive markers of neurodegenerative processes in obstructive sleep apnea patients.
- Trial name
- NCT06167369
- Where
- Germany
- Volunteers
- 136 people
- Sponsor
- Technische Universität Dresden
Stroke, Stroke (CVA) or TIA
The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)
Stroke is a major cause of death and disability worldwide, frequently resulting in persistent cognitive deficits among survivors.
- Conditions
- Stroke, Stroke (CVA) or TIA, Dementia, Vascular, Cerebrovascular Disorders
- Trial name
- IC3 (NCT05885295)
- Testing
- MRI brain, Blood tests, cognitive assessments
- Where
- United Kingdom
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Pediatric Traumatic Brain Injury
Validating a Blood Test for the Detection of Traumatic Brain Injury in Children
The primary objective of this study is to establish if Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1 (UCH-L1) are predictive of computed tomography (CT) findings in pediatric traumatic brain…
- Trial name
- NCT06940232
- Testing
- Blood Test for Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1 (UCH-L1) Acute Biomarkers
- Where
- United States
- Volunteers
- 330 people
- Sponsor
- University of Nebraska
Neurological Diseases or Conditions, Neurological Diseases Associated to Anti GFAP Antibodies
Neuropathy and Anti-GFAP Antibodies
Anti-Glial Fibrillary Acidic Protein (GFAP) are antibodies associated to inflammatory diseases of the central nervous system. The GFAP protein is highly expressed by astrocytes explaining these syndromes, but GFAP is also…
- Trial name
- Neuro-GFAP (NCT05742087)
- Testing
- Clinical examination, electroneuromyography (ENMG)
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Traumatic Brain Injury
Evaluation of Biomarker Kinetics After Mild Brain Injury Trauma
The primary objective of the clinical trial is to evaluate the effect of time on levels of Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) biomarker levels in a population of head injured…
- Trial name
- VIGILANT (NCT02541123)
- Testing
- Blood draw
- Where
- 10 sites in United States, Germany and 1 more
- Volunteers
- 194 people
- Sponsor
- Banyan Biomarkers, Inc
Head Injury Trauma, Traumatic Brain Injury, Mild
The PIONEER Comparative Effectiveness Study - Project 2
This is a pragmatic, open-label, multicenter, stepped-wedge, Type II hybrid effectiveness-implementation study. It is designed to evaluate both the comparative effectiveness and implementation feasibility of a…
- Trial name
- NCT07829107
- Testing
- Clinical pathway 1: Guidelines plus biomarkers, Clinical guidelines only
- Where
- 6 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- University of Michigan
Intracerebral Hemorrhage, Hemorrhagic Stroke
Outcome Prediction and Recovery After Spontaneous Intracerebral Haemorrhage
Spontaneous intracerebral haemorrhage (ICH) is a severe form of stroke with high mortality and frequent long-term disability. Current tools to predict how an individual patient will recover are limited.
- Trial name
- CR-4-Health (NCT07882784)
- Where
- 3 sites in Austria, Slovenia
- Volunteers
- 300 people
- Sponsor
- University Medical Centre Maribor
Dementia Disorders, Mild Cognitive Impairment (MCI)
Multimodal Biomarkers in Individual With Cognitive Impairment and Dementia
Memory problems can range from normal aging to mild cognitive impairment (MCI) to dementia. This study looks at three ways of measuring what is happening in the brain at each of these stages: a blood test (GFAP), a brain MRI…
- Trial name
- NCT07812480
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assiut University
Acute Stroke
Direct-to-angio Approach From loCal hOspitals Based on a PoInt-of-care bLOod Test for LVO
Direct-to-angio approach from loCal hOspitals based on a PoInt-of-care bLOod Test for LVO (COPILOT) is a multi-center, prospective, cluster-randomized crossover trial that will evaluate if the triage assessment to thrombectomy…
- Trial name
- COPILOT (NCT06910163)
- Testing
- Diagnostic standard of care, LVOne Test
- Where
- Puerto Rico
- Volunteers
- 520 people
- Sponsor
- Juan Vicenty
Donor Site Complication, Delirium
s100β, NSE n GFAP in Living Donor Hepatectomy and Delirium
The post-operative delirium picture is a serious and common complication seen after any major surgery, including hepatic resection.
- Conditions
- Donor Site Complication, Delirium, Uremic Encephalopathy, Neurologic Manifestations
- Trial name
- NCT04422925
- Testing
- Living Donor Hepatectomy
- Where
- Turkey (Türkiye)
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Akdeniz University
Multiple Sclerosis
Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease.
- Trial name
- NeurofilMS (NCT03981003)
- Testing
- Blood sample
- Where
- 28 sites in France, Martinique
- Volunteers
- 1,150 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Mild Traumatic Brain Injury
VIDAS® TBI Real Life Performance in Subjects With Mild Traumatic Brain Injury (mTBI)
Decision Rules for an initial CT-scan in patients arriving to Emergency Department (ED) and presenting a mild traumatic brain injury could be optimized by the use of an objective parameter easily and rapidly measured.
- Trial name
- NCT06449183
- Testing
- VIDAS® TBI Test [GFAP and UCH-L1 assays]
- Where
- 5 sites in United States
- Volunteers
- 903 people
- Sponsor
- BioMérieux
Subarachnoid Haemorrhage (SAH)
Serum GFAP and UCHL1: Evaluation of Their Predictive Value for SAH
To verify the analytical performance of GFAP and UCH-L1 biomarkers marketed by Abbott Diagnostics and to assess diagnostic accuracy of these biomarkers in predicting subarachnoid haemorrhage
- Trial name
- SAH (NCT06581757)
- Where
- United Kingdom
- Volunteers
- 144 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust